Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
New Affirm® Contrast Biopsy Technology Included in the Screening, Diagnosis, Treatment and Monitoring Solutions on Display
“As the global leader in breast imaging, we are committed to addressing the unmet needs of physicians and their patients across the continuum of breast care and we’re eager to engage with industry leaders at this year’s RSNA meeting to share our vision for the future of breast health,” said
Affirm Contrast Biopsy software allows clinicians to target and acquire tissue samples in lesions identified with I-View® Contrast-Enhanced Mammography software. The contrast solution provides healthcare facilities with a viable and attractive alternative to breast MRI, which historically has been used to find and biopsy more elusive lesions, such as those that cannot be seen via mammography or ultrasound. While breast MRI can be time-consuming and costly, contrast technology gives radiologists another option in the mammography suite that addresses these shortcomings.1,2 In a recent clinical study, 98% of patients had an overall positive opinion of their procedure experience with Affirm Contrast Biopsy software.3
RSNA attendees can experience Hologic’s portfolio at Booth 1911 in South
Hologic will also host a series of CME- and non-CME-accredited medical education symposiums and learning opportunities, accessible to attendees on-site and from remote locations. The medical education sessions include:
- “Upright Biopsy with Brevera® Breast Biopsy System: Real-Time Imaging, Verification & Automated Handling”
Sunday, Nov. 27: 11:45 a.m.– 12:45 p.m. CST
Krystal Airolawill demonstrate new upright breast biopsy technologies that will enhance accuracy, workflow and patient experience. She will share her experiences with the Affirm 2D/3D upright biopsy, lateral arm approach and Brevera Breast Biopsy system, which integrates tissue acquisition, real-time imaging and verification, and post-biopsy sample handling. Dr. Airolawill also share cases and explain how to significantly reduce the time and discomfort to patients in the biopsy suite while maximizing biopsy suite efficiencies and clinical decision-making.
- “Emerging Ultrasound Technology in Liver Surveillance”
Monday, Nov. 28: 12:00 p.m.– 1:00 p.m. CST
Learn more about the advancements in ultrasound technology with ShearWave™ Elastography. There are many opportunities to improve workflow efficiencies in liver surveillance that drive superior patient experiences and outcomes. In this lecture, participants will review comparisons with existing and emerging ultrasound technologies and techniques.
- “Current AI Applications in Mammography: Focus on Genius AI™ Detection Software”
Tuesday, Nov. 29: 12:00 p.m.– 1:00 p.m. CST
Attendees will hear from an expert on the benefits of artificial intelligence (AI) in mammography screening. With new high-resolution technologies being implemented, see how AI can reduce dose, file size and reading times. A focus will be on deep-learning AI and the benefits of Genius AI Detection software in clinical decision-making and increasing productivity.
- “Panel Discussion: Options in Localization”
Wednesday, Nov. 30: 12:00 p.m.– 1:00 p.m. CST
Join a multidisciplinary conversation on localization. Hear perspectives from leading radiologists and breast surgeons about what they like, what they use and why. What is the role of wires? What other technologies are available? What are the strengths and weaknesses of different options?
The company also champions women through the Hologic Global Women’s Health Index, which provides a science-backed data roadmap for improving women’s well-being, and Project Health Equality, which elevates awareness, research insights and access to quality care for underserved women. hologic.com
Hologic, 3D Mammography, 3Dimensions, Affirm, Brevera, Dimensions, Genius AI, I-View, Mach, Selenia, ShearWave, Supersonic, and The Science of Sure are trademarks and/or registered trademarks of
This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.
This information is not intended as a product solicitation or promotion where such activities are prohibited. For specific information on what products are available for sale in a particular country, please contact a local Hologic sales representative or write to firstname.lastname@example.org.
Publication for reference:
Hobbs MM, Taylor DB, Buzynski S, and Peake RE. Contrast-enhanced spectral mammography (CESM) and contrast MRI (CEMRI): Patient preferences and tolerance.
Hologic clinical study CSR-00266 Rev 001 2022
Vice President, Corporate Communications
Vice President, Investor Relations